Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1666 to 1680 of 7707 results

  1. Heart valve disease in adults

    Awaiting development [GID-QS10101] Expected publication date: TBC

    Quality standard
    Awaiting development

  2. Diverticular disease

    Awaiting development [GID-QS10086] Expected publication date: TBC

    Quality standard
    Awaiting development

  3. Taselisib for previously treated ER-positive, HER2-negative, PIK3CA-positive breast cancer in postmenopausal women ID1401

    In development [GID-TA10326] Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Infant, children and young people's experience of health care

    Awaiting development [GID-QS10102] Expected publication date: TBC

    Quality standard
    Awaiting development

  5. Ibrutinib for treating relapsed or refractory follicular lymphoma [1251]

    In development [GID-TA10223] Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Veliparib with carboplatin and paclitaxel for untreated non-squamous non-small-cell lung cancer [ID1277]

    In development [GID-TA10248] Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Shared decision-making: practical guidance for health and social care professionals

    Awaiting development [GID-QS10097] Expected publication date: TBC

    Quality standard
    Awaiting development

  8. Vocimagene amiretrorepvec with extended-release 5-fluorocytosine for treating recurrent high-grade glioma [ID1425]

    In development [GID-TA10542] Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Gosuranemab for treating progressive supranuclear palsy [ID1607]

    Awaiting development [GID-TA10553] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. MTX110 for untreated diffuse intrinsic pontine glioma [ID2695]

    In development [GID-TA10573] Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Atezolizumab for adjuvant treatment of resected high-risk muscle-invasive urothelial cancer [ID2730]

    In development [GID-TA10623] Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Cabotegravir with rilpivirine for the oral treatment of HIV-1 [ID3731]

    Awaiting development [GID-TA10604] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Avelumab for untreated PD-L1 positive recurrent or metastatic non-small-cell lung cancer [ID1261]

    In development [GID-TA10250] Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Lacosamide for adjunctive treatment of primary generalised tonic-clonic seizures in epilepsy [ID1687]

    In development [GID-TA10664] Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Baloxavir marboxil for influenza prophylaxis in people aged 12 and over [ID3793]

    Awaiting development [GID-TA10684] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development